文献速递其他结缔组织病

血清免疫球蛋白游离轻链是监测原发性干燥综合征疾病活动度和治疗反应的敏感生物标志物

Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

研究纳入100例疑似pSS患者(45例符合ACR-EULAR标准)及17例MALT淋巴瘤pSS患者,并分析利妥昔单抗(n=20)、安慰剂(n=10)或阿巴西普(n=15)治疗的纵向样本。血清FLCκ和FLCλ在pSS中显著高于非SS干燥患者,FLCκ/FLCλ比值异常见于11%的pSS患者,在无近期利妥昔单抗治疗的MALT-pSS患者中50%异常。FLC水平与ESSDAI和临床ESSDAI显著相关,利妥昔单抗或阿巴西普治疗显著降低FLC水平,FLC对变化敏感且相对变化高于IgG。

要点

  • pSS患者血清FLCκ和FLCλ水平显著高于非SS干燥患者,FLCκ/FLCλ比值异常见于11%的pSS患者。
  • 无近期利妥昔单抗治疗的MALT-pSS患者中50%存在FLCκ/FLCλ比值异常。
  • FLC水平与ESSDAI和临床ESSDAI显著相关,利妥昔单抗或阿巴西普治疗显著降低FLC水平。

核心结论

  • 血清FLC在pSS中升高,FLCκ/FLCλ比值异常可能提示MALT淋巴瘤的存在。
  • FLC水平可作为系统性疾病活动度的生物标志物并用于监测治疗反应。
  • FLC对变化敏感,且动力学优于IgG。

研究设计与样本

  • 纳入100例连续疑似pSS患者,其中45例符合ACR-EULAR的pSS标准。
  • 另纳入17例pSS合并MALT淋巴瘤患者及接受利妥昔单抗(n=20)、安慰剂(n=10)或阿巴西普(n=15)治疗的pSS患者纵向样本。
  • 血清FLCκ/FLCλ采用散射比浊法或透射比浊法测定。

主要发现

  • 诊断时pSS患者FLCκ和FLCλ血清水平显著高于非SS干燥患者。
  • 11%的pSS患者FLCκ/FLCλ比值异常。
  • 无近期利妥昔单抗治疗的MALT-pSS患者(n=12)中50%存在FLCκ/FLCλ比值异常。
  • 与IgG和抗SSA相比,FLC测定对pSS分类无额外价值。
  • FLC水平与ESSDAI和临床ESSDAI评估的系统性疾病活动度在横断面和纵向治疗后均显著相关。

关键数值与推荐

  • 45例患者符合ACR-EULAR的pSS标准。
  • 11%的pSS患者FLCκ/FLCλ比值异常。
  • 无近期利妥昔单抗治疗的MALT-pSS患者(n=12)中50%FLCκ/FLCλ比值异常。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Serum immunoglobulin free light chains (FLCs) are frequently elevated in B-cell-mediated autoimmune diseases, including primary SS (pSS). The objective of this study was to assess if serum FLCs can contribute to classification, mucosa-associated lymphoid tissue (MALT) lymphoma detection, monitoring of disease activity and treatment response in pSS. METHODS: Serum samples of 100 consecutive patients suspected of pSS were included. Forty-five patients fulfilled ACR-EULAR criteria for pSS. Additionally, samples of 17 pSS patients with MALT lymphoma and longitudinal samples of pSS patients treated with rituximab (n = 20), placebo (n = 10) or abatacept (n = 15) were included. Serum FLCκ/FLCλ was measured by nephelometry or turbidimetry. RESULTS: At diagnosis, FLCκ and FLCλ serum levels were significantly higher in pSS compared with non-SS sicca patients. The FLCκ/FLCλ ratio was abnormal in 11% of pSS patients. In established MALT-pSS patients, without recent rituximab treatment (n = 12), 50% had abnormal FLCκ/FLCλ ratios. FLC measurement had no additional value for pSS classification, compared with IgG and anti-SSA. FLC levels correlated significantly with systemic disease activity, assessed by EULAR SS Disease Activity Index (ESSDAI) and clinical ESSDAI, both cross-sectionally and longitudinally following treatment. Treatment with rituximab or abatacept significantly lowered FLC levels. FLCs show a large sensitivity to change and relative changes induced by treatment were higher compared with IgG. CONCLUSION: Serum FLCs are elevated in pSS, and abnormal FLCκ/FLCλ ratios may be indicative for the presence of MALT lymhoma. FLC levels can be used as a biomarker for systemic disease activity and monitoring treatment responses. FLCs are sensitive to change and have more favorable kinetics than IgG.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Verstappen GM, Moerman RV, van Nimwegen JF, et al. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome. Rheumatology (Oxford). 2018. PMID: 29982712. doi:10.1093/rheumatology/key180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。